13 completed, 9 active not recruiting, 5 terminated, 3 recruiting. 35 Phase 2, 4 Phase 1.
Follow Triple-Negative Breast Carcinoma: new trials by email Literature Review of Triple-Negative Breast Carcinoma trials Research Report on Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 60 | 2026-11-01 | 2026-10-16 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2026-10-01 | 2026-10-07 |
| Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC Biospecimen Collection, Breast Biopsy Procedure, Carboplatin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Recruiting | Vandana Abramson | 51 | 2025-09-09 | 2025-10-30 |
| Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer Biopsy of Breast, Biospecimen Collection, Breast Surgery - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 120 | 2025-05-14 | 2026-09-03 |
| STEMVAC in Patients With Early Stage Triple Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim - Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | University of Washington | 33 | 2022-11-17 | 2026-07-23 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations Alpelisib, Nab-paclitaxel - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2020-07-10 | 2026-07-07 |
| Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Abemaciclib, Therapeutic Conventional Surgery - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 26 | 2020-01-10 | 2025-11-12 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | Northwestern University | 12 | 2017-09-14 | 2026-06-17 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Atezolizumab, Biospecimen Collection, Carboplatin - Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 67 | 2017-08-02 | 2026-09-30 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer Mirvetuximab Soravtansine - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2017-06-05 | 2020-12-02 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 280 | 2017-03-31 | 2026-06-30 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Carboplatin, Paclitaxel, Panitumumab - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 43 | 2016-11-03 | 2025-11-06 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Breast Lump | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2016-10-06 | 2026-10-06 |
Showing 20 of 35. Sign in to see all of them.
Triple Negative Breast Neoplasms (35) · Breast Neoplasms (23) · Inflammatory Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Breast Neoplasms, Male (2) · Carcinoma, Renal Cell (2) · Edema (2) · Erythema (2) · Melanoma (2) · Neoplasm Metastasis (2) · Breast Carcinoma In Situ (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1)
Breast Diseases (35) · Neoplasms (35) · Neoplasms by Site (35) · Skin Diseases (35) · Skin and Connective Tissue Diseases (35) · Breast Neoplasms (12) · Neoplasms by Histologic Type (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Lung Diseases (3)
Paclitaxel (10) · Taxes (10) · Carboplatin (9) · pembrolizumab (9) · Cyclophosphamide (8) · Doxorubicin (8) · Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · Colony-Stimulating Factors (4) · Albumin-Bound Paclitaxel (3) · High-Energy Shock Waves (3) · Immunoglobulin G (3) · Panitumumab (3) · sargramostim (3) · 130-nm albumin-bound paclitaxel (2)
M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (9) · Mayo Clinic (3) · Northwestern University (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · Andrei Iagaru (1) · City of Hope Medical Center (1) · Emory University (1) · Laura Huppert, MD, BA (1) · University of Nebraska (1) · Vandana Abramson (1) · Vanderbilt-Ingram Cancer Center (1) · Virginia Commonwealth University (1)
United States (34) · Canada (1)
Clinton Yam (4) · Amulya C Yellala, MD (1) · Andrei M Iagaru, MD (1) · Azadeh Nasrazad, MD,PHD (1) · Azadeh Nasrazadani (1) · Bhuvaneswari Ramaswamy, MD (1) · Bora Lim, MD (1) · Carlos E. Vargas, MD (1) · Carlos H Barcenas (1) · Haeseong Park (1) · Harry D. Bear, M.D., Ph.D. (1) · Howard Bailey, MD (1) · James Waisman, MD (1) · Joseph W Kim (1) · Joyce F Liu (1)
PMID 23810467, PMID 24583822, PMID 25092775, PMID 25218906, PMID 26123926, PMID 32060053, PMID 35044810, PMID 37043123, PMID 37061619, PMID 37185961, PMID 37294342, PMID 39356138, PMID 39558017, PMID 42550611
P30CA006516 (2), P30CA060553 (2), P30CA068485 (2), U01CA062490 (2), UM1CA186689 (2), UM1CA186704 (2), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), P30CA006973 (1), P30CA013330 (1)